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Abstract: In this review, I introduce the strategy developed by our laboratory to explore the
mechanisms of renoprotection against progressive glomerulosclerosis leading to renal death. First, I
describe the experimental rat model in which disturbances of vascular regeneration and glomerular
hemodynamics lead to irreversible glomerulosclerosis. Second, I discuss the possible mechanisms
determining the progression of glomerulosclerosis and introduce a new imaging system based on
intravital confocal laser scanning microscopy. Third, I provide an in-depth review of the regulatory
glomerular hemodynamics at the cellular and molecular levels while focusing on the pivotal role
of Ca2D-dependent gap junctional intercellular communication in coordinating the behavior of
mesangial cells. Last, I show that local delivery of renoprotective agents, in combination with
diagnostic imaging of the renal microvasculature, allows the evaluation of the therapeutic eﬀects
of angiotensin II receptor and cyclooxygenase activity local blockade on the progression of
glomerulosclerosis, which would otherwise lead to renal death.
Keywords: chronic kidney disease, progressive glomerululosclerosis, renoprotection,
glomerular hemodynamics, in vivo imaging
Introduction
The number of chronic renal insuﬃciency
patients with need of hemodialysis or renal trans-
plantation has been increasing worldwide.1) In 2003,
more than 1 million patients worldwide, of whom
320,000 were in the United States, were receiving
maintenance dialysis.2) Similarly, 275,000 patients
were receiving maintenance dialysis in Japan in
2007.3) It has been proposed that glomerular hemo-
dynamic changes or glomerular growth responses
may promote the development of glomerulosclerosis
leading to renal insuﬃciency, irrespective of etiol-
ogy.4),5) However, the cellular and molecular mecha-
nisms leading to progressive glomerulosclerosis still
remain unclear. The ﬁnal goal of nephrologists is to
prevent the progression of glomerulosclerosis leading
to renal insuﬃciency, or to return the sclerotic lesions
to the non-perplexed condition in chronically pro-
gressive glomerular diseases such as diabetic nephro-
pathy and IgA nephritis. Here, I introduce new
insights into the pathogenesis of the disease, based on
accumulating evidence provided by others and us.
In addition, I present a novel approach for studying
local blockade of the renin–angiotensin system
(RAS) and the cyclooxygenase-dependent pathway
that consists in a confocal laser scanning microscopy-
based in vivo imaging system.
1. Establishment of an experimental model of
progressive glomerulosclerosis
Few experimental models exist that mimic
irreversible glomerulosclerosis. Of all, the 5/6 abla-
tion model has been the most used and the most
reliable one. Many lessons have been learnt from this
experimental model; importantly, that glomerular
hyperﬁltration, hyperfusion, hypertension, and hy-
pertrophy are associated with the progression of
glomerulosclerosis.4),5) Other experimental models of
progressive glomerulonephrits, such as the acceler-
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nephritis characterized by destructive or crescentic
glomerular lesions, diﬀer substantially from the
pathohistological features of the gradually accumu-
lating mesangial matrix seen in human diabetic
nephropathy and IgA nephropathy, eventually lead-
ing to chronic renal insuﬃciency.
We have originally reported that progressive
glomerulosclerosis can be induced in the rat by a 1-
shot injection of anti-Thy-1.1 monoclonal antibody
(antithymocyte serum [ATS]), followed by unilateral
nephrectomy.6) The antibody binds to a speciﬁc
epitope involved in endothelial–mesangial cell con-
tact.7),8) This experimental model has several advan-
tages in the analysis of progression factors leading to
irreversible glomerulosclerosis. First, the course of
disease between nephrectomized (1-kidney) and sham-
operated (2-kidney) groups can be directly compared
since the same amount of nephritogenic antibody is
bound to each kidney. Second, there is a clear-cut
diﬀerence in the prognosis of disease between the 1-
kidney and the 2-kidney models. The 1-kidney model
is characterized by progressive glomerulosclerotic
lesions with renal insuﬃciency, while the 2-kidney
model is fundamentally reversible,9) as shown in
Figs. 1–3. Third, the model can be applied to diﬀerent
rat strains, including the Munich Wistar rats in which
many glomeruli are located directly under the vicinal
surface of the kidney cortex,10),11) and genetically
modiﬁed Sprague Dawley rats, for instance, transgenic
rats carrying the enhanced green ﬂuorescent protein
(EGFP) transgene.12),13)
2. Risk factors for progressive glomerulosclerosis
Maintenance of normal glomerular function
requires a well-balanced physiological structure
composed of endothelial cells, mesangial cells, and
mesangial matrices. Upon glomerular damage, the
glomerular function may be impaired before eﬀective
repair of glomerular cells and matrix components
occurs. We showed that impairment of vascular
regeneration is strongly associated with the develop-
ment of progressive glomerulosclerosis in the 1-
kidney model, as compared with the 2-kidney
model.6) Semiquantitative analysis revealed that the
capillary density and mRNA expression of platelet/
endothelial cell adhesion molecule (PECAM)-1,
vascular cell adhesion molecule (VCAM)-1, and
vascular endothelial growth factor (VEGF) in the
glomeruli are signiﬁcantly lower in the 1-kidney
group on day 14 (an early stage of glomeruloneph-
ritis). On day 84, the 1-kidney group exhibited
progressive glomerulosclerotic lesions, followed by
a decrease in capillary density. In contrast, the
Fig. 1. Light microscopic ﬁndings in kidneys from an early stage of the 1-kidney and 2-kidney models. Diﬀuse mesangiolytic changes with
microaneurysmal ballooning were found in both models at day 3. Diﬀuse mesangial cell proliferation and mesangial matrix expansion
were observed at day 14 (PAS stain, 400#).
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ered to an almost normal structure.
Using EGFP-positive bone marrow (BM) chi-
meric rats, progressive glomerulosclerosis was in-
duced by a 1-shot injection of ATS, followed by
unilateral nephrectomy (1-kidney model).13) The
progression of glomerulosclerosis was so severe that
75% of the rats died, presumably of uremia, by 8
weeks after disease induction. To investigate micro-
vascular regeneration and glomerulosclerotic lesions
in BM chimeric rats, we examined the recruitment
of BM-derived cells in isolated glomeruli and frozen
sections. A confocal laser scan microscopic study
revealed that BM-derived PECAM-1DRECA-1D en-
dothelial cells and OX-7D mesangial cells which were
EGFP-positive and detectable for immunostaining
contribute to structurally support the glomerular
capillaries during chronicity of the disease.13)
Fig. 3. Scheme showing the disease courses of the 1-kidney and 2-kidney models. Anti-Thy-1 nephritis was induced in rats by
intravenous injection of 0.5mg of the anti-Thy-1.1 monoclonal antibody 1-22-3. Thirty minutes after injection, unilateral
nephrectomy of the right kidney was performed (1-kidney model). In the 2-kidney model, a sham operation was performed 30 minutes
after injection of the same dose of antibody.
Fig. 2. Light microscopic ﬁndings in kidneys from a late stage of the 1-kidney and 2-kidney models. On day 84, the histological changes
between the 1-kidney and 2-kidney models were sharply diﬀerent. Severe mesangial cell proliferation and matrix expansion, often
accompanied by sclerotic changes, were observed in the majority of the glomeruli in the 1-kidney model. Diﬀuse tubular atrophic
changes with interstitial cell inﬁltration were also found. In contrast, only mild mesangial proliferative changes were found in the 2-
kidney model. No pathological changes were observed in the nephrectomy control group (PAS stain, 50# [upper left panel] and 400#
[all other panels]).
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the hemodynamic events occurring in the glomerular
circulation under physiopathological conditions. To
that purpose, we have developed an intravital real-
time confocal laser scanning microscope system in
combination with ﬂuorescent tracer labeling,14) as
shown in Fig. 4 and the supplemental video movie.
This imaging system has allowed the examination of
not only glomerular hemodynamic changes but also of
the morphological recovery of the glomerular capil-
laries after glomerular injury with a noninvasive
procedure in Munich Wistar rats. The sequence of
hemodynamic changes within the glomeruli was
analyzed in the reversible 2-kidney and irreversible
1-kidney ATS models.15) The determining point in
glomerulosclerosis progression occurs during the peri-
od from 7 to 14 days after disease induction, when
disturbances of local intraglomerular blood ﬂow
Fig. 4. Scheme of the confocal laser scanning microscope and sequential images showing glomerular microcirculation. A confocal laser
scanning microscope (CSU-10; Yokogawa Electric Company, Tokyo, Japan) in combination with an image-intensiﬁed charge-coupled
device video camera (C2400-89; Hamamatsu Photonics KK, Shizuoka, Japan) was used for real-time observation of renal
microcirculation, including glomerular blood ﬂow. The left kidney was exposed by a ﬂank and muscle fascia incision, followed by the
analysis of microcirculation from the surface of the kidney. Vascular images were obtained by intravenous injection of a solution of
ﬂuorescein isothiocyanate (FITC)-labeled dextran (molecular weight 150,000Da). To measure blood ﬂow, a batch of autologous red
blood cells labeled with FITC was injected into the tail vein. In the lower panels, the sequential images of glomerular microcirculation
from a normal Munich Wistar rat are presented. Arrows show the sequential images of the same red blood cell ﬂow. VTR: videotape
recorder, TV: television. In addition, the real image of glomerular blood ﬂow can be seen in the additional video movie.
Additional video movie. Representative movie of glomerular blood ﬂow in the normal Munich Wistar rat (http://joi.jlc.jst.go.jp/JST-
J-STAGE/pjab/87.81).
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that disturbance of local intraglomerular blood ﬂow
showing a signiﬁcant diﬀerence in blood ﬂow velocity
at two diﬀerent ﬁxed parts of tufts within a
glomerulus, which we called “turbulence of glomerular
hemodynamics,” far precedes progressive glomerulo-
sclerosis, observed 84 days after disease induction.
From the viewpoint of hemodynamics, it is well known
that a turbulent ﬂow requires more pressure for a
given ﬂow rate than a laminar ﬂow does.16) Therefore,
it is reasonable to consider that disturbances in
intraglomerular blood ﬂow in the 1-kidney model
may induce higher shear and hydrostatic stresses
along the glomerular capillary walls in the early phase
of renal disease, leading to retardation of capillary
repair and, ﬁnally, to progressive glomerulosclerosis.
Such an abnormal blood ﬂow in the 1-kidney model is
aggravated at the late stage of glomerulosclerosis, as
shown in the sequential video frames of Fig. 5 in which
the images of “stop,”“ reﬂow,” and “retrograde ﬂow”
were caught in the interstitial microvasculature.
3. Potential roles of mesangial cell–intercellular
communication in the juxtaglomerular area
In the normal glomerulus, the glomerular base-
ment membrane encloses the endocapillary region,
which is composed of a capillary lumen, endothelial
cells, mesangial cells, and mesangial matrices. This
specialized compartment has a passageway through
which cell–cell or cell–matrix communicate with the
juxtaglomerular area, where aﬀerent and eﬀerent
arteries, renin-producing granular cells, and macula
densa cells play pivotal roles in the coordinate
regulation of glomerular hemodynamics (Fig. 6).
Mesangial cells form a tree-like branching network
from the hilar site to the glomerular tufts, and connect
with each other through gap junctions present in glo-
merular and extraglomerular mesangial cells (Fig. 6).
Fig. 5. Sequential images showing abnormal blood ﬂow in the renal interstitium at a late stage of the 1-kidney model. The sequential
images of blood ﬂow in the renal interstitial vessel were obtained from a rat with progressive glomerulosclerosis of the one-kidney
model, 20 weeks after disease induction. Frames from No. 1 to No. 3 show the sequential images of the same RBC ﬂow, indicating the
upward ﬂow. White arrows in frames No. 4 to No. 6, between the times 52.53 second to 54.45 second, show almost no moving of RBC,
indicating the ‘stop’ ﬂow. Frames from No. 7 to No. 9 show the sequential images of the same RBC ﬂow, indicating the downward
ﬂow or ‘retrograde’ ﬂow.
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junctions provide the mesangium with the character-
istics of a functional syncytium.17)–20) The gap
junctions are formed by a family of special proteins,
the connexins (Cx). To date, more than 20 diﬀerent
Cx proteins have been identiﬁed. In vitro studies
using cultured mesangial cells have conﬁrmed that
the gap junctions expressed at cell–cell contacts are
functional.17),18) Microinjection of lucifer yellow into a
single mesangial cell resulted in the transmission of
the dye through a network of about 10–20 cells. The
addition of platelet-derived growth factor (PDGF),
known as the most potent mitogen for mesangial cells
and an active player in mesangial cell contraction
and extracellular matrix synthesis, causes a rapid and
transient inhibition of gap junctional intercellular
communication. This response to PDGF is remark-
ably inhibited by treatment of mesangial cells with
a phosphatidylinositol 3-kinase (PI3K) inhibitor.
PI3K has multiple eﬀects on a variety of signaling
molecules associated with protein kinase C or
mitogen-activated protein kinase activation.17) Fur-
thermore, we showed that mechanical stimulation of
mesangial cells results in the propagation of a Ca2D
wave through the gap junctions. This Ca2D wave can
be inhibited by the gap junction inhibitor heptanol as
well as by a phospholipase C inhibitor, suggesting a
mediating role of inositol triphosphate (IP3) in the
initiation and transmission of intercellular Ca2D
signaling. Injection of IP3 into a single mesangial
cell causes contraction, not only in the targeted cell
but also in the adjacent cells.18)
Ideally, the integrated functions of renal micro-
circulation, propagation of a Ca2D wave, and
coordinated mesangial cell contraction should be
examined in in vivo or ex vivo systems. Peti-Peterdi
et al. reported very interesting data concerning
macula densa sensing and signaling mechanisms by
using a reﬁned technique of isolated and micro-
perfused aﬀerent artery–juxta glomerular appara-
tus–glomerulus.20),21) Activation of tubuloglomerular
feedback by increasing tubular ﬂow rate at the
macular densa rapidly produces a signiﬁcant eleva-
tion of intracellular Ca2D in extraglomerular mesan-
gial cells and renin granular cells. Subsequently, cell-
to-cell propagation of calcium signaling is observed
upstream toward proximal segments of the aﬀerent
and adjacent glomeruli, as well as toward intra-
glomerular elements, including the most distant
podocytes. The same Ca2D wave has been observed
in nonperfusing, adjacent glomerulus, causing vaso-
constriction and contraction of the glomerular tuft.21)
Using an isolated, perfused kidney model and
gap junctional inhibitors such as speciﬁc Cx-mimetic
Fig. 6. Mechanisms involved in the progression of glomerulosclerosis. Schema of juxtaglomerular apparatus and glomerulus is shown in
addition to the key molecules regulating the glomerular hemodynamics. AII: angiotensin II, ATP: adenosine triphosphate, NO: nitric
oxide, PGs: prostaglandins.
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tion of the nonselective gap junction uncoupler 18 ,-
glycyrrhetinic acid and the Cx43 mimetic peptide
signiﬁcantly elevated perfusion pressure while Cx37
and Cx40 had no eﬀect.22) Using Tie-Cre recombinase
and renin-Cre recombinase mice, Wagner et al.
reported that endothelial Cx40 is not essential for
the control of systemic blood pressure and renin
expression.23) Thus, clarifying the molecular and
subcellular mechanisms of Cx-mediated renal micro-
circulation in the pathophysiological settings awaits
future studies, using reﬁned methods of genetic
engineering.
4. Search for therapeutic strategies aimed at
enhancing recovery from progressive
glomerulosclerosis, focusing
on local delivery of drugs
In clinical situations, drug therapies for glomer-
ulonephritis should be established after the nephritic
symptoms are diagnosed. Therefore, it would be
important to identify the determining point in the
progression of reversible and irreversible glomerulo-
sclerosis, as stressed previously.24) As shown in Fig. 6,
we focused on developing therapeutic approaches
that target 3 possible mechanisms involved in the
determination of the critical point of glomeruloscle-
rosis progression. First, we targeted BM-derived stem
cells to stimulate recovery from progressive glomer-
ulosclerosis.25) EGFP! BM chimeric rats were infused
with BM cells from EGFPD donors once (at day 7)
after induction of the 1-kidney model of ATS
glomerulonephritis, presumably at the critical point
determining the irreversible progression of glomer-
ulosclerosis. BM cell infusion improved renal function
and glomerular hemodynamics, and ameliorated
histological alterations with reduced glomerular
inﬁltration of macrophages, leading to dramatically
reduced mortality. Only 2 of 8 untreated rats
survived 12 weeks after disease induction, while 5 of
6 BM cell-infused rats survived until 12 weeks. In the
BM cell-infused group, urinary protein excretion,
serum creatinine, and blood urea nitrogen levels were
signiﬁcantly lower than in the untreated group from
day 8 until 12 weeks after disease induction.
It is now well accepted that substances that
block the RAS exert a beneﬁcial eﬀect on the
progression of glomerular diseases that would other-
wise result in renal insuﬃciency.26) There is also
increasing evidence that intrarenal RAS within
glomeruli and interstitial tissues, including renal
tubules, is not only involved in physiological proc-
esses, but also in pathological conditions, such as
vascular remodeling, diabetic nephropathy, and
glomerulosclerosis.27)–30) Therefore, we attempted to
block intrarenal RAS by using of a novel approach
that applies renal subcapsular implantation of a
collagen sponge as a means to deliver angiotensin II
receptor blocker (ARB) locally.31) At day 7 after
induction of the 1-kidney model of ATS glomerulo-
nephritis, pellets of type-1 collagen containing
phosphate-buﬀered saline, ARB (Valsartan), angio-
tensin II, or angiotensin II D ARB, were implanted
into the subrenal capsular pocket. Local ARB
treatment signiﬁcantly reduced proteinuria, and
ameliorated glomerular pathology, including glomer-
ular matrix expansion and the sclerotic index. In
addition, glomerular blood ﬂow levels were also
signiﬁcantly improved compared to the untreated
disease group.
Prostaglandins (PGs) modulate renal function,
including hemodynamics and water and salt homeo-
stasis. These eicosanoids are formed by the cyclo-
oxygenase (COX)-dependent metabolism of arach-
idonic acid. COX-2 is constitutively expressed in
the macula densa of the juxtaglomerular apparatus
and in adjacent epithelial cells of the cortical thick
ascending limb of Henle.32) Preliminarily, we exam-
ined the pharmacological eﬀects of 2 contrastive
agents (a selective COX-2 inhibitor and a prostacy-
clin analogue, PGI2) on the course of the disease in
the 1-kidney model of ATS glomerulonephritis. The
local delivery of a COX-2 inhibitor at day 7 after
disease induction slowed the progression of glomer-
ulosclerosis. In contrast, local administration of
PGI2 induces vasodilation and consequent glomerular
hyperperfusion. PGI2 is thus considered to render
the load of hyperperfusion on the inﬂamed glomeruli,
leading to aggravated glomerular lesion. These
results are consistent with our running hypothesis
that disturbance of intraglomerular microcirculation
is a risk factor for progressive glomerulosclerosis.24)
On the other hand, it is known that COX-2 inhibitors
induced acute renal failure, similar to that observed
with nonselective COX inhibitor.33) In anti-Thy-1
glomerulonephritis, selective COX-2 inhibitors,
rofecoxib or celcoxib, impaired glomerular capillary
repair after mesangiolysis, probably due to the
inhibition of endothelial cell migration, and shape
change.34) Compared to the oral administration of
selective inhibitor of COX-2, beginning at 18-hour
disease induction up to day 5 in this study, we
administered a selective inhibitor of COX-2 only once
beneath the renal capsule at a fully established stage
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ance between these studies could be explained the
diﬀerent timing and pathway of drug delivery.
Diabetic nephropathy is the leading cause of
end-stage renal disease in developed countries.35) It
has been reported that blocking RAS slows the pro-
gression of established diabetic nephropathy.36)–38)
To conﬁrm the role of angiotensin II in renal
hemodynamics in diabetic rats, we examined the
eﬀects of a selective ARB on renal hemodynamic
changes in vivo using streptozotocin (STZ)-induced
diabetic rats.39) The kidney-to-body weight ratio,
glomerular volume, and the diameters of aﬀerent
arterioles and eﬀerent arterioles, erythrocyte veloc-
ities within glomeruli, volume ﬂow in the glomerular
capillary loops in 4-day diabetes mellitus (DM) were
signiﬁcantly higher than in control rats, and these
increases were even more pronounced in 28-day DM.
The ratio of the diameter of the aﬀerent artery to the
diameter of the eﬀerent artery in 28-day DM was
markedly increased when compared with control and
4-day DM groups, indicating a continuous increase in
internal glomerular pressure with time. Oral admin-
istration of ARB for 28 days starting 24 hours after
STZ injection resulted in amelioration of all these
parameters and signiﬁcantly decreased proteinuria.
Furthermore, subrenal capsular treatment with ARB
also reduced urinary protein excretion. In addition,
local delivery of ARB attenuated monocyte/
macrophage inﬁltration into the glomeruli and the
enhanced glomerular expression of endothelial nitric
oxide (NO) synthesis both at the mRNA and protein
levels.40) These results indicate that ARB acts as
an anti-inﬂammatory drug during the early phases
of STZ-induced diabetic nephropathy. Activation of
NF-5B, a well-known player in inﬂammation and the
immune response, can be measured as the increase
in expression of the p65 subunit of NF-5B, and its
translocation from the cytoplasm to the nucleus in
both tubular epithelial and glomerular cells from
the diabetic kidney. Local ARB treatment induced a
reduction in p65 nuclear localization and staining
intensity. In Zucker fatty rats, the calcium-depend-
ent protease calpain plays a role in reducing
endothelial nitric oxide synthase activity and NO
availability, leading to endothelial dysfunction and
vascular inﬂammation.41) In our study, glomerular
expression of 145/150-kDa spectrin breakdown prod-
ucts, speciﬁc of calpain activation, was dramatically
increased in diabetic rats. Remarkably, the protein
expression reverted to the normal level after local
ARB treatment.
5. Concluding remarks
State-of-the-art strategies are now available to
delay or prevent the potentially irreversible progres-
sion of glomerular diseases to renal insuﬃciency.
Taking into account the current knowledge described
in this review article, I would like to draw some
concluding remarks. Local delivery of renoprotective
agents such as RAS and COX-2 inhibitors can be
applied to successfully control glomerular hemo-
dynamics and attenuate glomerular inﬂammation
although further study will be needed for clinical
use. Furthermore, noninvasive diagnostic devices for
measuring glomerular function parameters, including
hemodynamics, permeability, and contractibility,
should be developed to objectively diagnose the stage
of progression and to examine the pharmacological
eﬀect of established or newly developed drugs. For
example, reﬁned photonic probes and imaging
systems that have an excellent speciﬁcity and high
resolution have promising clinical applications.
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